GLP3-RT (Retatrutide)

Human clinical Weight Loss & Metabolism In 1 protocol 2 sources

Retatrutide is an investigational triple hormone receptor agonist that targets GLP-1, GIP, and glucagon receptors. Clinical trials have shown unprecedented weight loss efficacy, surpassing dual agonists, by combining appetite suppression with increased energy expenditure.

01Dosing reference

Amount

N/A - Investigational Drug

Frequency

N/A - Investigational Drug

Cycle

N/A - Investigational Drug

Reference figures, not a recommendationThese values reflect amounts described in the literature and vendor documentation this database indexes. Use the reconstitution calculator to convert them into syringe units.

02Mechanism of action

Triple Receptor Agonism

Binds to and activates GLP-1, GIP, and glucagon receptors simultaneously.

Synergistic Metabolic Regulation

GLP-1 and GIP reduce appetite and improve insulin secretion, while glucagon receptor activation increases energy expenditure and fat oxidation.

Enhanced Weight Loss

The combined triple action leads to greater reductions in body weight and liver fat compared to single or dual incretin therapies.

03Human evidence

Achieved up to 24.2% weight loss at 48 weeks in Phase 2 trials.

Phase 2 randomized, double-blind, placebo-controlled trial in adults with obesity.

Significant reduction in liver fat, resolving non-alcoholic fatty liver disease (NAFLD) in a majority of patients.

Sub-study of the Phase 2 trial involving patients with NAFLD.

04Preclinical evidence

Increased energy expenditure and lipolysis beyond what is seen with GLP-1/GIP dual agonists.

Murine models comparing triple agonism to dual and single agonists.

Improved glucose tolerance and robust body weight reduction.

Preclinical studies in non-human primates and diet-induced obese rodent models.

05What is known vs. unknown

Reasonably established

Retatrutide is a 'triple G' agonist targeting GLP-1, GIP, and Glucagon receptors.
It has demonstrated the highest weight loss percentage in Phase 2 trials among incretin-based therapies to date.
Glucagon receptor activation specifically helps increase basal metabolic rate and liver fat clearance.
It is currently in Phase 3 clinical trials (TRIUMPH program) for obesity and related conditions.

Unknowns & limits

Long-term cardiovascular outcomes and safety profile are still being evaluated in Phase 3 trials.
The exact contribution of the glucagon component to long-term weight maintenance versus potential risks (like increased heart rate) requires further study.

06Safety & regulatory context

Regulatory statusRetatrutide is an investigational drug and is not yet FDA-approved. In clinical trials, the most common side effects are gastrointestinal, including nausea, diarrhea, vomiting, and constipation, similar to other incretin-based therapies. There are also dose-dependent increases in heart rate, likely due to the glucagon and GLP-1 components. It is currently undergoing extensive Phase 3 testing to fully establish its safety profile.

07Compared with Tirzepatide

GLP3-RT (Retatrutide) vs. Tirzepatide

Key difference

Tirzepatide is a dual agonist (GLP-1 and GIP), whereas Retatrutide adds a third mechanism (Glucagon receptor agonism) to further increase energy expenditure.

When researchers discuss each

Tirzepatide is discussed as an approved, highly effective dual-action treatment for type 2 diabetes and obesity, while Retatrutide is discussed as the next-generation investigational therapy pushing the boundaries of pharmacological weight loss.

08Appears in protocols

⚡ Advanced Metabolic Protocol

1-3 mg/week (titrate up from 1 mg)Once weekly

09Glossary

Incretin

Metabolic hormones that stimulate a decrease in blood glucose levels and are released after eating.

Glucagon

A hormone that typically raises blood sugar but also increases energy expenditure and fat breakdown when activated alongside GLP-1.

Agonist

A substance that initiates a physiological response when combined with a receptor.

10Knowledge check

Q1Which three receptors does Retatrutide target?

Q2What unique benefit does the glucagon receptor activation add to Retatrutide compared to dual agonists?

Q3Which statement best reflects a documented limitation of the current clinical evidence for Retatrutide?

Q4Which statement accurately summarizes the dossier's comparison between Retatrutide and Tirzepatide?

Q5Which safety or regulatory statement about Retatrutide is supported by the dossier?

11Sources

More in Weight Loss & Metabolism

See all

AOD-9604

Weight Loss & Metabolism

Human clinical

AOD-9604 is a modified fragment of human growth hormone (HGH) that includes amino acids 177-191. Research indicates it mimics the fat-burning effects of HGH by stimulating lipolysis and inhibiting lipogenesis, without the adverse effects on blood sugar or tissue growth typically associated with full-length HGH.

250-500 mcg/day

MOTS-c

Weight Loss & Metabolism

Early human

MOTS-c is a naturally occurring mitochondrial-derived peptide that plays a key role in regulating metabolic homeostasis and energy production. Research indicates it acts as an 'exercise mimetic' by activating AMPK, improving insulin sensitivity, and enhancing physical performance in animal models.

5-10 mg

SLU-PP-332

Weight Loss & Metabolism

Preclinical only

SLU-PP-332 is a novel investigational compound known as an 'exercise mimetic' that activates estrogen-related receptors (ERRs). Preclinical research indicates it can enhance endurance, increase fat oxidation, and promote weight loss without altering food intake or requiring physical exercise. It is currently being studied for its potential to treat metabolic disorders and muscle wasting conditions.

Not established for humans (Preclinical: 25 mg/kg in mice)

Research and educational use onlyNothing on this site is medical advice, a prescription, or a recommendation for human use. Compounds documented here are research chemicals. Consult a qualified clinician before making any health decision.